SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+25.2%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$697M
AUM Growth
+$697M
(-5.3%)
Cap. Flow
-$125M
Cap. Flow
% of AUM
-17.88%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
97
New
21
Increased
21
Reduced
26
Closed
24
Top Buys
| 1 |
Vericel Corp
VCEL
|
$14.1M |
| 2 |
Celcuity
CELC
|
$10.7M |
| 3 |
HCA Healthcare
HCA
|
$8.29M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$7.81M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.65M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$29.6M |
| 2 |
Illumina
ILMN
|
$25.7M |
| 3 |
CVS Health
CVS
|
$17.8M |
| 4 |
Envista
NVST
|
$15.7M |
| 5 |
Eli Lilly
LLY
|
$15.3M |
Sector Composition
| 1 | Healthcare | 97.09% |
| 2 | Consumer Staples | 1.8% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CVS Health
CVS
$93B
| $8.83M | 1.27% |
94,754
-191,146
| -67% | -$17.8M |
|
|
27
HCA Healthcare
HCA
$95.4B
| $8.29M | 1.19% |
+34,550
| New | +$8.29M |
|
|
THER
28
DELISTED
THERATECHNOLOGIES INC COM
THER
| $7.77M | 1.11% |
8,799,125
+791,411
| +10% | +$699K |
|
|
BCYC
29
Bicycle Therapeutics
BCYC
$492M
| $7.65M | 1.1% |
+258,400
| New | +$7.65M |
|
30
Axogen
AXGN
$718M
| $7.54M | 1.08% |
755,998
+331,000
| +78% | +$3.3M |
|
31
Avidity Biosciences
RNA
$6.12B
| $6.88M | 0.99% |
+310,000
| New | +$6.88M |
|
32
Enanta Pharmaceuticals
ENTA
$189M
| $6.41M | 0.92% |
137,814
+14,800
| +12% | +$688K |
|
|
JBIO
33
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $6.36M | 0.91% |
+217,119
| New | +$6.36M |
|
34
Orthofix Medical
OFIX
$583M
| $6.06M | 0.87% |
+295,300
| New | +$6.06M |
|
35
4D Molecular Therapeutics
FDMT
$302M
| $5.66M | 0.81% |
+254,700
| New | +$5.66M |
|
36
Syndax Pharmaceuticals
SNDX
$1.39B
| $5.6M | 0.8% |
+220,000
| New | +$5.6M |
|
|
DICE
37
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $5.41M | 0.78% |
173,447
-361,911
| -68% | -$11.3M |
|
38
STAAR Surgical
STAA
$1.35B
| $5.35M | 0.77% |
+110,200
| New | +$5.35M |
|
39
Enovis
ENOV
$1.75B
| $5.08M | 0.73% |
95,000
-7,100
| -7% | -$380K |
|
|
40
Illumina
ILMN
$15.2B
| $4.91M | 0.7% |
24,262
-127,338
| -84% | -$25.7M |
|
41
89bio
ETNB
$1.37B
| $4.82M | 0.69% |
379,000
+49,000
| +15% | +$624K |
|
42
DexCom
DXCM
$30.9B
| $4.53M | 0.65% |
40,000
+16,164
| +68% | +$1.83M |
|
|
IMGO
43
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $4.13M | 0.59% |
115,000
-98,000
| -46% | -$3.52M |
|
44
Axsome Therapeutics
AXSM
$6.09B
| $3.86M | 0.55% |
+50,000
| New | +$3.86M |
|
|
CELL
45
DELISTED
PhenomeX Inc. Common Stock
CELL
| $3.56M | 0.51% |
+1,330,000
| New | +$3.56M |
|
46
Neuropace
NPCE
$310M
| $3.53M | 0.51% |
2,369,003
+35,000
| +1% | +$52.2K |
|
47
Pharvaris
PHVS
$1.41B
| $3.49M | 0.5% |
+310,000
| New | +$3.49M |
|
|
RXDX
48
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $3.42M | 0.49% |
+31,100
| New | +$3.42M |
|
49
TG Therapeutics
TGTX
$5.03B
| $2.82M | 0.4% |
+238,000
| New | +$2.82M |
|
50
Transmedics
TMDX
$3.65B
| $2.68M | 0.39% |
43,500
-131,800
| -75% | -$8.13M |
|